维普中文期刊产品整合服务
45篇 您的检索式:作者名="Kiser A"
    题名 作者 年代 出处 被引量
1Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions显示文摘AIM To quantify drug-drug-interactions(DDIs) encountered in patients prescribed hepatitis C virus(HCV) treatment, the interventions made, and the time spent in this process.METHODS As standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral(DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir(LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir(OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.RESULTS Six hundred and sixty four patients(83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients. CONCLUSION DDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care.Jacob A Langness Matthew Nguyen Amanda Wieland Gregory T Everson Jennifer J Kiser 2017World Journal of Gastroenterology2017,23,9:5
2To surcharge or not to surcharge: An empirical investigation of ATM pricing 显示文摘Hannah T H Kiser E K Prager R A 2003The Review of Economics and Statistics2003,85,4:1
3Spectroscopic investigation of Cr( Ⅲ ) -and Cr( VI ) -treated nanoscale zerovalent iron显示文摘Manning B A Kiser J R Kwon H 2007Environ SciTechnot2007,41,2:1
4Ionization and dissociation processes in phosphorus thichloride anddiphosphorus tetrachloride 显示文摘Sandoval A A Moser H C Kiser R W 1963The Journal of Physical Chemistry1963,67,1:1
5Biosorption of nanoparticles to heterotrophic wastewater biomass显示文摘Kiser M A Ryu H Jang H 2010Water Research2010,44,14:1
6Titanium nanomateri- al removal and release from wastewater treatment plants 显示文摘Kiser M A Westerhoff P Benn T 2009Environmental science & technology2009,43,17:1
7Biosorption of nanop-articles to heterotrophic wastewater biomass显示文摘Kiser M A Ryu H Jang H 2010WaterRes2010,44,14:1
8Biosorption of nanoparticles to heterotrophic wastewater biomass显示文摘Kiser M A Ryu H Jang H 2010water research2010,44,14:1
9The role of binder content on microstmcture and properties of a Cu-base active brazing filler metal for diamond and cBN显示文摘ELSENER H R KLOTZ U E KHALID F A PIAZZA D KISER M 2005Advanced Engineering Materials2005,7,5:1
10Reduction and immobilization of chromium(Ⅵ)by iron(Ⅱ)-treated faujasite显示文摘Jon R Kiser Bruce A Manning 2010Journal of Hazardous Materials2010,174,:1
11Spectroscopic investigation of Cr(Ⅲ)and Cr(Ⅵ)treated nanoscale zerovalent iron显示文摘Manning B A Kiser J R Kwon H 2007Environ Sci Technol2007,41,:1
12Gold mineralization in high-grade metamorphic shear zones of the Renco Mine,Southern Zimbabwe 显示文摘Kisers A F M Kolb J Meyer F M 1998Economic Geology1998,93,:1
13Spectroscopic investigation of Cr( III)- and Cr(VI)-treated nanoscale zerovalent iron 显示文摘Manning B A Kiser J R Kwon H 2007Environmental Science & Technology2007,41,2:1
14Evaluation of ultra-high temperature ceramics foraeropropulsion use显示文摘Stanley R Levine Elizabeth J Opila Michael C Halbig James D Kiser Mrityunjay Singh Jonathan A Salem 2002Journal of the European Ceramic Society2002,,14:1
15Titanium nanomaterial removal and release from wastewater treatment plants 显示文摘KISER M A WESTERHOFF P BENN T 2009Environmental Science and Technology2009,43,17:1
16Titanium nanomaterial removal and release from wastewater treatment plants显示文摘Kiser M A Westerhoff P Benn T 0,,17:1
17An expectation confirmation perspective of medical tourism显示文摘Chou S Y Kiser A I T Rodriguez E L 2012Journal of Service Science Research2012,4,2:1
18Thermoacoustic CT:Imaging Principles显示文摘R A KRUGER W L KISER K D MILLER 2000Proc SPIE2000,3916,:1
19Reduction and immobilization of chromium(Ⅵ)by iron(Ⅱ)-treated faujasite显示文摘Kiser J R Manning B A 2010Journal of Hazardous Materials2010,174,13:1
20Reduction and immobilization of chromi- um(VI)by iron( II ) treated faujasite显示文摘J R Kiser B A Manning 2010Journal of Hazardous Materi- als2010,174,13:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费